[1]孙小燕,杨雷,王蕾,等.基于多准则决策模型评价芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血的效益-风险[J].西部中医药,2024,37(10):109-114.[doi:10.12174/j.issn.2096-9600.2024.10.25]
　SUN Xiaoyan,YANG Lei,WANG Lei,et al.Effectiveness-risk Evaluation of Qili Qiangxin Capsules and Iron in the Treatment of Heart Failure with Iron-deficiency Anemia Based on Multi-criteria Models for Decision-making[J].Western Journal of Traditional Chinese Medicine,2024,37(10):109-114.[doi:10.12174/j.issn.2096-9600.2024.10.25]
点击复制

基于多准则决策模型评价芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血的效益-风险
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年10期
页码:
109-114
栏目:
临床研究
出版日期:
2024-10-15

文章信息/Info

Title:
Effectiveness-risk Evaluation of Qili Qiangxin Capsules and Iron in the Treatment of Heart Failure with Iron-deficiency Anemia Based on Multi-criteria Models for Decision-making
作者:
孙小燕, 杨雷, 王蕾, 屈伶玉, 赵玉清, 狄巨岚, 刘学英, 柴志强, 吴泽阳
张家口市第一医院，河北 张家口 075000
Author(s):
SUN Xiaoyan, YANG Lei, WANG Lei, QU Lingyu, ZHAO Yuqing, DI Julan, LIU Xueying, CHAI Zhiqiang, WU Zeyang
Zhangjiakou City First Hospital, Zhangjiakou 075000, China
关键词:
心力衰竭; 缺铁性贫血; 芪苈强心胶囊; 多准则决策分析; 效益; 风险
Keywords:
heart failure; iron-deficiency anemia; capsules; multi-criteria decision-making analysis; effectiveness; risk
分类号:
R256.21
DOI:
10.12174/j.issn.2096-9600.2024.10.25
文献标志码:
B
摘要:
目的基于多准则决策模型评价芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血的效益-风险。 方法将80例心力衰竭合并缺铁性贫血患者按随机数字表法分为对照组和研究组各40例。对照组在常规治疗基础上予芪苈强心胶囊，研究组在对照组治疗基础上联合铁剂治疗，持续治疗3个月。比较两组患者治疗前后6分钟步行试验的步行距离（the six minutes walking distance，6MWD）、左心室收缩末期内径（left ventricular end systolic diameter，LVESD）、左心室舒张末期内径（left ventricular end-diastolic dimension，LVEDD）、左心室射血分数（left ventricular ejection fraction，LVEF），血清内N末端B型利尿钠肽原（N-terminal B-type prodiuretic natriuretic peptide，NT-proBNP）和超敏C反应蛋白（high-sensitivity C-reactive protein，hs-CRP）表达水平。建立芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血多准则决策分析模型。比较两组效益指标和风险指标效应值，并评价模型的灵敏度。 结果治疗后，研究组患者LVESD、LVEDD及血清NT-proBNP、hs-CRP水平均低于对照组（P＜0.05），而6MWD、LVEF高于对照组（P＜0.05）；研究组总有效率［90.00%（36/40）］高于对照组［77.50%（31/40）］（P＜0.05）；研究组不良反应发生率［10.00%（4/40）］低于对照组［30.00%（12/40）］（P＜0.05）；研究组和对照组的效益值分别为83和47，风险值分别为26和25，效益-风险总值分别为55和36，研究组的效益-风险总值最高；无论效益-风险的相对权重如何改变，模型评价结果均保持不变。 结论芪苈强心胶囊联合铁剂能有效改善心力衰竭合并缺铁性贫血患者的预后，降低患者不良反应发生率。
Abstract:
ObjectiveTo assess the effectiveness-risk of Qili Qiangxin capsules combined with iron in the treatment of heart failure and iron-deficiency anemia based on multi-criteria models for decision-making. MethodsEighty patients were allocated to the control group and the study group according to random number table method with 40 cases in each group. The control group took Qili Qiangxin capsules on the foundation of conventional therapy, iron was administered to the study group based on the therapy of the control group, and both groups were treated for three months consecutively. To compare 6MWD, LVESD, LVEDD, LVEF, the expressions of NT-proBNP and hs-CRP before and after the treatment between the two groups. To establish the multi-criteria models for decision-making in the treatment of heart failure and iron-deficiency anemia with Qili Qiangxin capsules and iron. To compare the effect values of benefit and risk indicator between both groups, and to evaluate the sensitivity of the model. ResultsAfter the treatment, LVESD, LVEDD, the levels of NT-proBNP and hs-CRP in the study group were lower than these of the control group (P<0.05), while 6MWD and LVEF higher than these in the control group (P<0.05); total effective rate of the study group was [90.00%(36/40)], higher than [77.50%(31/40)] of the control group (P<0.05); the incidence of adverse reaction of the study group was [10.00%(4/40)], lower than [30.00%(12/40)] of the control group (P<0.05); the effect values of the study group and the control group were 83 and 47 respectively, risk values were 26 and 25 respectively, total values of effectiveness-risk were 55 and 36 respectively, total value of effectiveness-risk was the highest in the study group; the results of the model evaluation remained the same regardless of the change in the the relative weighting of effectiveness-risks. ConclusionQili Qiangxin capsules combined with iron could effectively improve the prognosis of heart failure and iron-deficiency anemia, and reduce the incidence of adverse reaction.

相似文献/References:

[1]宋吉法.ACEI、ARB联合参松养心胶囊治疗慢性心力衰竭42例疗效观察[J].西部中医药,2012,25(07):63.
　SONG Ji-fa.Observation on Clinical Effects of ACEI and ARB Combined with ShenSong YangXin Capsule in Treating 42 Cases of Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2012,25(10):63.
[2]王盛强.辨证论治慢性心力衰竭临床观察[J].西部中医药,2014,27(06):78.
　WANG Shengqiang.On Treating Chronic Heart Failure by Syndrome Differentiation and Treatment[J].Western Journal of Traditional Chinese Medicine,2014,27(10):78.
[3]赵嘉晶,曹飞,岳瑶函,等.慢性心力衰竭患者 LDH 与血浆 BNP 及中医证型相关性研究[J].西部中医药,2014,27(09):78.
[4]刘玉霞,王亚红△,王硕仁,等.冠心病临床心力衰竭(阶段C)患者证治规律研究[J].西部中医药,2015,28(03):1.
[5]吉利,张艳.益气通脉饮对慢性心力衰竭大鼠心功能及血清TNF-α、IL-6、TGF-β1水平的影响[J].西部中医药,2015,28(05):25.
[6]陶玲,杜涛,缪金龙,等.芪苈强心胶囊对老年缺血性心肌病伴心力衰竭患者血浆NT-proBNP水平的影响[J].西部中医药,2015,28(08):75.
[7]王艳飞,任越,曹雪滨△,等.充血性心力衰竭患者临床资料中医证候量表的评价[J].西部中医药,2015,28(12):68.
[8]杨晓霞,丁延虹△,杨衍涛,等.参附注射液对慢性充血性心力衰竭患者血清BNP、CRP、TNF-α、IL-6水平的影响[J].西部中医药,2012,25(09):3.
　YANG Xiao-xia,DING Yan-hong,YANG Yan-tao,et al.Effect of ShenFu Injection on Levels of BNP, CRP, TNF-α and IL-6 in Serum of Patients with Chronic Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2012,25(10):3.
[9]赵晓新,刘丽萍.临床护理路径在慢性充血性心力衰竭患者健康教育中的应用效果评价[J].西部中医药,2013,26(08):117.
　ZHAO Xiaoxin,LIU Liping.Evaluation on Clinical Nursing Pathway Applied to Health Education of Patients with Chronic Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2013,26(10):117.
[10]刘冬梅,邹剑杰,罗晓敏,等.益阴助阳、活血通脉法治疗充血性心力衰竭临床观察[J].西部中医药,2014,27(07):62.
　LIU Dongmei,ZOU Jianjie,LUO Xiaomin,et al.Clinical Observation on Treating Congestive Heart Failure by the Method of Tonifying Yin-Yang, Activating Blood and Freeing Vessels[J].Western Journal of Traditional Chinese Medicine,2014,27(10):62.

备注/Memo

备注/Memo:
孙小燕（1982—），女，副主任医师。研究方向：心衰的治疗。张家口市重点研发计划项目（2121151D）。
更新日期/Last Update: 2024-10-15